Irreversible Electroporation (NanoKnife ®) and Immunotherapy for the Treatment of Stage IV Colorectal Cancer
Condition: Liver Metastasis Colon Cancer Interventions: Combination Product: IRE plus checkpoint inhibitor; Combination Product: IRE plus Checkpoint Inhibitor plus CpG-ODN Sponsor: University of Saskatchewan Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Prospective Observational Study to Predict the Response of Biliary Tract Tumors to Immunotherapy
Conditions: Biliary Tract Tumor; Cholangiocarcinoma Intervention: Other: Blood samples, tumor biopsy specimens will be collected Sponsor: Zhejiang Cancer Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Irreversible Electroporation (NanoKnife ®) and Immunotherapy for the Treatment of Stage IV Colorectal Cancer
Condition: Liver Metastasis Colon Cancer Interventions: Combination Product: IRE plus checkpoint inhibitor; Combination Product: IRE plus Checkpoint Inhibitor plus CpG-ODN Sponsor: University of Saskatchewan Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Prospective Observational Study to Predict the Response of Biliary Tract Tumors to Immunotherapy
Conditions: Biliary Tract Tumor; Cholangiocarcinoma Interventions: Other: Blood samples, tumor biopsy specimens will be collected Sponsors: Zhejiang Cancer Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Irreversible Electroporation (NanoKnife ®) and Immunotherapy for the Treatment of Stage IV Colorectal Cancer
Conditions: Liver Metastasis Colon Cancer Interventions: Combination Product: IRE plus checkpoint inhibitor; Combination Product: IRE plus Checkpoint Inhibitor plus CpG-ODN Sponsors: University of Saskatchewan Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC
Conditions: Hepatocellular Carcinoma; Chemotherapy Effect; Chemotherapeutic Toxicity Interventions: Drug: Oxaliplatin,calcium folinic acid, levofolinic acid, 5-FU; Drug: Concurrent Lenvatinib; Drug: Concurrent PD-1 antibody; Drug: Sequential Lenvatinib; Drug: Sequential PD-1 antibody Sponsors: Sun Yat-sen University; The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine; Affiliated Hospital of Guangdong Medical University; First People's Hospital of Foshan Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 18, 2023 Category: Research Source Type: clinical trials
Primary Tumor Radiotherapy Omitting CTV for Patients With Advanced NSCLC Responded to Immunotherapy and Chemotherapy
Conditions: Advanced Non-Small Cell Squamous Lung Cancer; Radiotherapy; Immunotherapy Intervention: Radiation: CTV omitted or delineated Sponsor: Hubei Cancer Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 14, 2023 Category: Research Source Type: clinical trials
